BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-254@pharmaconomics
DTSTAMP:20260707T003624Z
DTSTART;VALUE=DATE:20260825
DTEND;VALUE=DATE:20260826
SUMMARY:JAZZ PDUFA — zanidatamab
DESCRIPTION:The FDA's approval decision on zanidatamab for HER2+ 1L gastroesophageal adenocarcinoma is due Aug 25\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1232524/000119312526009899/d61589dex991.htm\n\nTrack it: https://pharmaconomics.com/e/254
URL:https://pharmaconomics.com/e/254
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:JAZZ catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR